Elsevier

Contraception

Volume 70, Issue 1, July 2004, Pages 11-18
Contraception

Original research article
Pharmacokinetics, ovulation suppression and return to ovulation following a lower dose subcutaneous formulation of Depo-Provera®

https://doi.org/10.1016/j.contraception.2004.01.011Get rights and content

Abstract

Depo-Provera® is a highly effective contraceptive, given intramuscularly (150 mg/mL) once every 3 months. It has been in use in the United States for over 10 years. A new lower-dose formulation of Depo-Provera (104 mg/0.65 mL), has been developed that allows subcutaneous injection, potentially increasing the convenience, ease of administration and tolerability of this contraceptive. This prospective, randomized, single-center, single-dose trial evaluates the pharmacokinetics of the lower-dose formulation of Depo-Provera and compares the lower-dose formulation to the original formulation with regard to efficacy and duration of ovulation suppression and the return to ovulation at 12 months. While delivering a 30% lower total dose than the intramuscular formulation, the lower-dose formulation of Depo-Provera suppressed ovulation for more than 13 weeks in all subjects and was not affected by body mass index or race. Median time for return to ovulation was 30 weeks, with a 97.4% cumulative rate of return to ovulation at 12 months.

Introduction

Depo-Provera® (medroxyprogesterone acetate, intramuscular injection [IM DMPA]); is a highly effective injectable contraceptive that has been used in the United States for over 10 years [1], and worldwide for over 30 years [2]. Over the past decade, this option has become an increasingly popular choice for hormonal contraception among US women, and the decline in unintended pregnancy rates during this time has been attributed in part to the increased use of long-acting contraceptives such as IM DMPA [3], [4]. Requiring only one injection every 3 months, this method results in a low “typical use” failure rate that is comparable to the rate with “perfect use” (0.3%) [5]. Thus, typical use rates for IM DMPA are similar to those reported for the 5-year Mirena® (levonorgestrel intrauterine system) and surgical sterilization, and much better than the typical use rate for the most prevalently used hormonal method, daily oral contraceptives (OCs) [6], [7], [8], [9]. This consistency between perfect use and typical use may be attributable to both the need for less frequent dosing and the fact that antiovulatory concentrations of medroxyprogesterone acetate (MPA) are achieved within 24 h of injection, providing immediate protection against pregnancy when used within the first week of menses [10]. Among currently available hormonal methods, IM DMPA and Mirena are immediately effective, whereas oral, patch and vaginal ring contraceptives generally require a backup method for the first 7 days of use [11], [12].

The new, lower dose formulation of Depo-Provera (104 mg/0.65 mL) allows administration by subcutaneous (SC DMPA) rather than intramuscular injection, and is expected to be therapeutically equivalent to the original formulation. This formulation is expected to have comparable if not improved tolerability relative to the intramuscular formulation, due to its lower dose. Although similar trends have been seen with lowering of hormone dose in combination OCs (i.e., estrogen), concerns include the possibility of reduced efficacy in general or in certain patient subtypes, such as those with higher body mass index (BMI) [13]. Another concern that may be raised for methods that have a longer duration of contraceptive effect is ease of reversibility and potential for delayed return to fertility.

The objectives of this pharmacokinetic/pharmacodynamic (PK/PD) study were to assess and compare the efficacy and duration of ovulation suppression, and return to ovulation at 12 months following a single injection of either SC DMPA or IM DMPA. Additional objectives were to determine the PK profile of MPA when given via subcutaneous route and to assess the potential influence of BMI and ethnicity. For the purpose of comparison, data on 24 women given SC DMPA from a separate PK study conducted in Singapore are included and will be addressed in the discussion (data on file).

Section snippets

Methods

The dose selection for SC DMPA was determined in a previous dose-ranging PK/PD study, in which a total of 47 women received a single injection of 50 mg, 75 mg, 100 mg or 150 mg/0.5 mL SC DMPA (data on file). The 100-mg injection was the lowest dose that effectively suppressed ovulation for at least 91 days. The SC DMPA developed for the current trial is a new formulation with 16% weight/volume resulting in a final dose of 104 mg/0.65 mL. Therefore, the formulation and composition of SC DMPA

Demographic characteristics

A total of 19 and 39 patients were considered evaluable in the IM DMPA and the SC DMPA groups, respectively. Table 1 presents the demographic characteristics of evaluable subjects from this study (conducted at a single center in Los Angeles, CA). For the purpose of comparison, data are also presented for 24 Asian women who received SC DMPA in a separate study conducted in Singapore. The Singapore study data will be addressed in the discussion portion of this article. Women in the IM DMPA and SC

Discussion

This PK/PD study demonstrated that a single injection of SC DMPA (a new formulation containing 104 mg MPA/0.65 mL) provided immediate suppression of ovulation and consistently suppressed ovulation in study subjects over the 91-day (13-week) dosing interval. Analysis of the PK of MPA after SC injection showed similar MPA parameters for black, white, and Asian subjects, indicating that the efficacy of the lower-dose formulation was independent of race. Furthermore, suppression of ovulation was

Acknowledgements

The authors would like to thank Dr. Yeong Cheng Toh, MD, of the KK Women's and Children's Hospital in Singapore, China, for supplying pharmacokinetic data in Asian women from a separate study conducted in Singapore.

References (18)

There are more references available in the full text version of this article.

Cited by (101)

  • Return to ovulation after Sayana Press is injected every 4 months for one year: Empirical and pharmacokinetic/pharmacodynamic modeling results

    2022, Contraception: X
    Citation Excerpt :

    The latter presumed each woman has her own intrinsic threshold value, with approximately 10% of women ovulating at MPA levels exceeding 0.1 ng/mL and a median threshold of 0.07 ng/mL [11]. However, we also performed a sensitivity analysis that conservatively assumed 10% of women ovulate at MPA levels exceeding 0.2 ng/mL; a fixed level cited as sufficient to ensure a contraceptive effect in some previous studies [13,14]. We estimated pharmacokinetic model parameters and MPA levels over time for a typical woman (analogous to median levels in our model framework) using maximum likelihood, and predicted return to ovulation for a population of women with similar weight distribution as the Ovulation Cohort using Monte Carlo simulations.

  • Ovulation suppression following subcutaneous administration of depot medroxyprogesterone acetate

    2022, Contraception: X
    Citation Excerpt :

    There are several limitations to our analysis, most importantly the absence of participants with class II+ obesity (BMI ≥35). We did not observe consistent trends between risk of ovulation and BMI in the range of 18 to 34, which agrees with earlier reports [6]. However, this does not mean our results necessarily apply to women with more extreme BMI.

  • Pharmacokinetics, metabolism and serum concentrations of progestins used in contraception

    2021, Pharmacology and Therapeutics
    Citation Excerpt :

    Only two studies directly compare the two MPA formulations. One study assessed the levels of other reproductive hormones (E2, P4, follicle stimulating hormone) in parallel but not MPA levels (Jain et al., 2004); the other study only directly compared MPA levels at 6 months, 1 year and 2 years (Kaunitz, Darney, Ross, Wolter, & Speroff, 2009), making it impossible to reliably compare their tmax and Cmax values. To date, only one study has attempted measurement of MPA levels in cervical secretions.

View all citing articles on Scopus
View full text